Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.27-1.2%$8.48$7.21▼$20.46$1.92B0.732.89 million shs2.34 million shsANIPANI Pharmaceuticals$77.65-1.1%$81.26$62.60▼$99.50$1.77B0.43303,523 shs157,981 shsANVSAnnovis Bio$1.66-5.4%$1.86$1.54▼$5.50$57.51M1.19837,616 shs1.03 million shsLNTHLantheus$104.82+1.1%$103.36$47.25▼$111.86$6.82B-0.06868,576 shs474,086 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-5.05%-5.16%-26.55%-51.92%ANIPANI Pharmaceuticals0.00%-1.96%-6.76%-1.26%+16.07%ANVSAnnovis Bio0.00%-4.83%0.00%-5.59%-37.19%LNTHLantheus0.00%-2.57%-3.84%+24.30%+42.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.27-1.2%$8.48$7.21▼$20.46$1.92B0.732.89 million shs2.34 million shsANIPANI Pharmaceuticals$77.65-1.1%$81.26$62.60▼$99.50$1.77B0.43303,523 shs157,981 shsANVSAnnovis Bio$1.66-5.4%$1.86$1.54▼$5.50$57.51M1.19837,616 shs1.03 million shsLNTHLantheus$104.82+1.1%$103.36$47.25▼$111.86$6.82B-0.06868,576 shs474,086 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-5.05%-5.16%-26.55%-51.92%ANIPANI Pharmaceuticals0.00%-1.96%-6.76%-1.26%+16.07%ANVSAnnovis Bio0.00%-4.83%0.00%-5.59%-37.19%LNTHLantheus0.00%-2.57%-3.84%+24.30%+42.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.50Moderate Buy$18.67125.72% UpsideANIPANI Pharmaceuticals 2.67Moderate Buy$105.0035.22% UpsideANVSAnnovis Bio 2.60Moderate Buy$11.67604.93% UpsideLNTHLantheus 2.73Moderate Buy$110.435.35% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026ANIPANI Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$91.007/16/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $125.007/15/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform ➝ Market Outperform$115.00 ➝ $120.007/15/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $17.007/10/2026ANIPANI Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$124.007/9/2026ANVSAnnovis Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/7/2026ANVSAnnovis Bio Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/6/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/6/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.76$0.65 per share12.64$2.01 per share4.11ANIPANI Pharmaceuticals$883.37M2.00$9.93 per share7.82$24.03 per share3.23ANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ALNTHLantheus$1.54B4.43$6.38 per share16.42$16.43 per share6.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.168.27N/A32.43%39.98%28.08%8/5/2026 (Estimated)ANIPANI Pharmaceuticals$78.34M$3.9519.668.98N/A9.98%27.51%10.02%8/7/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/11/2026 (Estimated)LNTHLantheus$233.56M$4.1525.2619.48N/A18.05%29.32%15.00%8/5/2026 (Estimated)Latest ANIP, ADMA, ANVS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ANVSAnnovis Bio-$0.44N/AN/AN/AN/AN/A8/7/2026Q2 2026ANIPANI Pharmaceuticals$2.01N/AN/AN/A$260.13 millionN/A8/5/2026Q2 2026ADMAADMA Biologics$0.16N/AN/AN/A$125.34 millionN/A8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$362.45 millionN/A5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ANIPANI Pharmaceuticals1.063.122.52ANVSAnnovis BioN/A1.271.27LNTHLantheus0.472.832.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%LNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANIPANI Pharmaceuticals8.10%ANVSAnnovis Bio20.80%LNTHLantheus1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableANIP, ADMA, ANVS, and LNTH HeadlinesRecent News About These CompaniesHealthcare of Ontario Pension Plan Trust Fund Raises Stock Holdings in Lantheus Holdings, Inc. $LNTHJuly 26 at 5:44 AM | marketbeat.comEpoch Investment Partners Inc. Purchases 242,222 Shares of Lantheus Holdings, Inc. $LNTHJuly 26 at 4:15 AM | marketbeat.comCalifornia Public Employees Retirement System Grows Position in Lantheus Holdings, Inc. $LNTHJuly 26 at 3:36 AM | marketbeat.comAssetmark Inc. Sells 95,805 Shares of Lantheus Holdings, Inc. $LNTHJuly 25 at 3:15 AM | marketbeat.comLantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern TimeJuly 23 at 9:00 AM | globenewswire.comLantheus Holdings to Host Second Quarter 2026 Conference Call and Webcast on August 6July 23 at 8:51 AM | quiverquant.comQLantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of "Moderate Buy" by AnalystsJuly 18, 2026 | marketbeat.comTruist Financial Forecasts Strong Price Appreciation for Lantheus (NASDAQ:LNTH) StockJuly 18, 2026 | americanbankingnews.comLantheus (NASDAQ:LNTH) Price Target Raised to $125.00July 16, 2026 | marketbeat.comRadioMedix Appoints Brian A. Markison to Board of DirectorsJuly 15, 2026 | globenewswire.comTeachers Retirement System of The State of Kentucky Purchases 12,943 Shares of Lantheus Holdings, Inc. $LNTHJuly 15, 2026 | marketbeat.com3 reasons to avoid LNTH and 1 stock to buy insteadJuly 14, 2026 | msn.comLantheus (NASDAQ:LNTH) Stock Price Expected to Rise, B. Riley Financial Analyst SaysJuly 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS) and Lantheus (LNTH)June 30, 2026 | theglobeandmail.comFDA manufacturing issues delay Lantheus' tumor imaging kitJune 29, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Lantheus (LNTH)June 28, 2026 | theglobeandmail.comLantheus Holdings, Inc.: Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)June 27, 2026 | finanznachrichten.deLantheus Application for Tumor Imaging Drug Rejected Due to Manufacturing ConcernsJune 27, 2026 | marketwatch.comUS FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issuesJune 27, 2026 | msn.comUS FDA declines to approve Lantheus' tumor imaging kitJune 26, 2026 | reuters.comLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)June 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANIP, ADMA, ANVS, and LNTH Company DescriptionsADMA Biologics NASDAQ:ADMA$8.27 -0.10 (-1.19%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.29 +0.02 (+0.19%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$77.65 -0.88 (-1.12%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$80.00 +2.35 (+3.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$1.66 -0.10 (-5.43%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.68 +0.03 (+1.81%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Lantheus NASDAQ:LNTH$104.82 +1.09 (+1.05%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$103.50 -1.32 (-1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
